Evotec SE expects to reduce its workforce by up to 800 people and close down more business sites in its drive to regain momentum following a two-year slowdown in the market for drug discovery and preclinical development. The Germany-based company is one of Europe’s larger biotech service and drug development organisations with a global presence in manufacturing. It is a Nasdaq-listed company which had a market capitalisation of €969 million on 31 December 2025.
